37. 膿疱性乾癬（汎発型） Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AIN457
NOVARTIS FARMA S.p.A.
2014 Phase 3 EUCTR2013-003086-34-IT Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Novartis Farmacéutica, S.A.
2013 Phase 3 EUCTR2013-003086-34-ES Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Novartis Pharma K.K.
2013 Phase 3 JPRN-JapicCTI-132305 -
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-003086-34-PL Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2014 Phase 3 EUCTR2013-003086-34-BE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 EUCTR2013-003086-34-SE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 EUCTR2013-003086-34-GB Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 EUCTR2013-003086-34-AT Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
AIN457,
Novartis Pharma Services AG
2013 Phase 3 EUCTR2013-003086-34-DE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
ANB019
AnaptysBio Inc.
2022 Phase 3 EUCTR2021-001448-90-FR Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001448-90-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001447-27-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2021 Phase 3 EUCTR2021-001448-90-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2021-001447-27-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004021-33-GB United Kingdom;United States;
AnaptysBio, Inc.
2019 Phase 2 NCT03619902 Korea, Republic of;Poland;United Kingdom;United States;
Acitretin
Department of Dermatology, Children's Hospital of Chongqing Medical University
2021 Phase 0 ChiCTR2100044690 China;
Institute of dermatology, Chinese Academy of Medical Sciences
2011 - ChiCTR-TRC-12003542 China;
Shanghai Dermatology Hospital
2020 Phase 0 ChiCTR2000037099 China;
Adalimumab
AbbVie
2015 Phase 3 NCT02533375 Japan;
Alefacept
The Guenther Dermatology Research Centre
2005 Phase 2 NCT00301002 Canada;
Alvarez 2
AnaptysBio Inc.
2018 Phase 2 EUCTR2017-004021-33-GB United Kingdom;United States;
Anakinra
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2013 Phase 2 NCT01794117 United States;
Anti-IL-36R monoclonal antibody
AnaptysBio Inc.
2022 Phase 3 EUCTR2021-001448-90-FR Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001448-90-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001447-27-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2021 Phase 3 EUCTR2021-001448-90-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2021-001447-27-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004021-33-GB United Kingdom;United States;
BI 655130
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2018-003081-14-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2018-003081-14-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2018-003081-14-GR Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España S.A.
2022 Phase 2 EUCTR2018-003080-56-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España, S.A.
2020 Phase 2 EUCTR2018-003081-14-ES Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim France
2020 Phase 2 EUCTR2018-003081-14-FR Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
2019 Phase 3 EUCTR2018-003080-56-FR Australia;China;France;Germany;Greece;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
2019 Phase 2 EUCTR2017-004231-37-FR France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
Boehringer Ingelheim Netherlands BV
2020 Phase 2 EUCTR2018-003081-14-NL Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2018-003081-14-DE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2019 Phase 2 EUCTR2018-003080-56-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2018-003081-14-HR Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003081-14-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003080-56-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
- Phase 2 EUCTR2018-003081-14-CZ Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
SCS Boehringer Ingelheim Comm. V
- Phase 2 EUCTR2018-003081-14-BE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
BI655130
Boehringer Ingelheim
2016 Phase 1 NCT02978690 France;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;Tunisia;
Brodalumab
Kyowa Hakko Kirin Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142430 -
2013 Phase 3 JPRN-JapicCTI-132057 -
Brodalumab 210mg SC
Kyowa Kirin Co., Ltd.
2016 Phase 4 NCT04183881 Japan;
CNTO1959
JANSSEN CILAG INTERNATIONAL NV
2019 Phase 3 EUCTR2018-003206-58-IT France;Germany;Italy;Spain;United Kingdom;
Janssen-Cilag International N.V.
2019 Phase 3 EUCTR2018-003206-58-GB France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-FR France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-ES France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-DE France;Germany;Italy;Spain;United Kingdom;
Calcitriol
Probiodrug AG
2007 - EUCTR2006-005344-83-DE Germany;
Efalizumab
Technische Universität Dresden
2007 - EUCTR2007-003922-70-DE Germany;
Guselkumab
Janssen Pharmaceutical K.K.
2015 Phase 3 NCT02343744 Japan;
Janssen-Cilag Ltd.
2019 Phase 3 NCT03998683 France;Germany;Italy;Spain;United Kingdom;
Infliximab
TOYAMA SATOSHI
2018 - JPRN-jRCTs031180367 Japan;
The University of Tokyo Hospital
2017 - JPRN-UMIN000027208 Japan;
Infliximab [infliximab biosimilar 3]
Pfizer
2019 - NCT03885089 Japan;
Ixekizumab
Eli Lilly and Company
2019 Phase 4 NCT03942042 Japan;
KHK4827
Kyowa Hakko Kirin Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142430 -
2013 Phase 3 JPRN-JapicCTI-132057 -
Kyowa Hakko Kirin Company, Limited
2013 Phase 3 NCT01782937 Japan;
KHK4827 140mg SC
Kyowa Kirin Co., Ltd.
2014 Phase 3 NCT02052609 Japan;
KHK4827 210mg SC
Kyowa Kirin Co., Ltd.
2014 Phase 3 NCT02052609 Japan;
LY3074828
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
MONOCLONAL ANTIBODY ANTI-IGG1
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2018-003081-14-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2018-003081-14-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2018-003081-14-GR Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España S.A.
2022 Phase 2 EUCTR2018-003080-56-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España, S.A.
2020 Phase 2 EUCTR2018-003081-14-ES Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim France
2020 Phase 2 EUCTR2018-003081-14-FR Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
2019 Phase 3 EUCTR2018-003080-56-FR Australia;China;France;Germany;Greece;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
2019 Phase 2 EUCTR2017-004231-37-FR France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
Boehringer Ingelheim Netherlands BV
2020 Phase 2 EUCTR2018-003081-14-NL Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2018-003081-14-DE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2019 Phase 2 EUCTR2018-003080-56-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2018-003081-14-HR Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003081-14-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003080-56-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
- Phase 2 EUCTR2018-003081-14-CZ Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
SCS Boehringer Ingelheim Comm. V
- Phase 2 EUCTR2018-003081-14-BE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Melatonin
Department of Dermatology, Children's Hospital of Chongqing Medical University
2021 Phase 0 ChiCTR2100044690 China;
Mirikizumab
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
Oxymatrine
General Hospital of Ningxia Medical University
2018 Phase 0 ChiCTR2100043193 China;
P32/98
Probiodrug AG
2007 - EUCTR2006-005344-83-DE Germany;
Placebo
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
Raptiva
Technische Universität Dresden
2007 - EUCTR2007-003922-70-DE Germany;
Risankizumab
AbbVie
2017 Phase 3 NCT03022045 Japan;
Secukinumab
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
Novartis Pharma K.K.
2013 Phase 3 JPRN-JapicCTI-132305 -
Novartis Pharmaceuticals
2013 Phase 3 NCT02008890 Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 NCT01952015 Japan;
Secukinumab 150 mg/1 mL Solution for injection
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-003086-34-BE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Silikis 3µg/g Salbe
Probiodrug AG
2007 - EUCTR2006-005344-83-DE Germany;
Spesolimab
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2018-003081-14-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2018-003081-14-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim
2022 Phase 3 NCT05239039 -
2022 Phase 3 NCT05200247 Japan;
2020 Phase 2 NCT04399837 Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
2020 Phase 2 JPRN-JapicCTI-205387 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
2019 Phase 2 NCT03886246 Argentina;China;France;Germany;Japan;Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan;Thailand;Tunisia;Turkey;United States;
2019 Phase 2 NCT03782792 China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2018-003081-14-GR Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España S.A.
2022 Phase 2 EUCTR2018-003080-56-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España, S.A.
2020 Phase 2 EUCTR2018-003081-14-ES Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim France
2020 Phase 2 EUCTR2018-003081-14-FR Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim Netherlands BV
2020 Phase 2 EUCTR2018-003081-14-NL Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2018-003081-14-DE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2019 Phase 2 EUCTR2018-003080-56-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2018-003081-14-HR Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003081-14-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003080-56-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
- Phase 2 EUCTR2018-003081-14-CZ Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
SCS Boehringer Ingelheim Comm. V
- Phase 2 EUCTR2018-003081-14-BE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Yamada Nobuko
2021 Phase 2 JPRN-jRCT2041210087 Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea;Malaysia;Mexico;Netherlands;Philippines;Poland;Russia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;
TA-650
Mitsubishi Tanabe Pharma Corporation
2012 Phase 3 NCT01680159 Japan;
TG
Institute of dermatology, Chinese Academy of Medical Sciences
2011 - ChiCTR-TRC-12003542 China;
TREMFYA®
Janssen-Cilag International N.V.
2019 Phase 3 EUCTR2018-003206-58-GB France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-FR France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-ES France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-DE France;Germany;Italy;Spain;United Kingdom;
Ustekinumab
Innovaderm Research Inc.
2010 Phase 3 NCT01091051 Canada;
NOVARTIS FARMA S.p.A.
2014 Phase 3 EUCTR2013-003086-34-IT Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Novartis Farmacéutica, S.A.
2013 Phase 3 EUCTR2013-003086-34-ES Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Novartis Pharma K.K.
2013 Phase 3 JPRN-JapicCTI-132305 -
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-003086-34-PL Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2014 Phase 3 EUCTR2013-003086-34-BE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 EUCTR2013-003086-34-SE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 EUCTR2013-003086-34-GB Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 EUCTR2013-003086-34-AT Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
AIN457,
Novartis Pharma Services AG
2013 Phase 3 EUCTR2013-003086-34-DE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
ANB019
AnaptysBio Inc.
2022 Phase 3 EUCTR2021-001448-90-FR Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001448-90-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001447-27-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2021 Phase 3 EUCTR2021-001448-90-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2021-001447-27-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004021-33-GB United Kingdom;United States;
AnaptysBio, Inc.
2019 Phase 2 NCT03619902 Korea, Republic of;Poland;United Kingdom;United States;
Acitretin
Department of Dermatology, Children's Hospital of Chongqing Medical University
2021 Phase 0 ChiCTR2100044690 China;
Institute of dermatology, Chinese Academy of Medical Sciences
2011 - ChiCTR-TRC-12003542 China;
Shanghai Dermatology Hospital
2020 Phase 0 ChiCTR2000037099 China;
Adalimumab
AbbVie
2015 Phase 3 NCT02533375 Japan;
Alefacept
The Guenther Dermatology Research Centre
2005 Phase 2 NCT00301002 Canada;
Alvarez 2
AnaptysBio Inc.
2018 Phase 2 EUCTR2017-004021-33-GB United Kingdom;United States;
Anakinra
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2013 Phase 2 NCT01794117 United States;
Anti-IL-36R monoclonal antibody
AnaptysBio Inc.
2022 Phase 3 EUCTR2021-001448-90-FR Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001448-90-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2022 Phase 3 EUCTR2021-001447-27-ES Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
2021 Phase 3 EUCTR2021-001448-90-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2021 Phase 3 EUCTR2021-001447-27-DE Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004021-33-GB United Kingdom;United States;
BI 655130
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2018-003081-14-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2018-003081-14-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2018-003081-14-GR Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España S.A.
2022 Phase 2 EUCTR2018-003080-56-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España, S.A.
2020 Phase 2 EUCTR2018-003081-14-ES Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim France
2020 Phase 2 EUCTR2018-003081-14-FR Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
2019 Phase 3 EUCTR2018-003080-56-FR Australia;China;France;Germany;Greece;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
2019 Phase 2 EUCTR2017-004231-37-FR France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
Boehringer Ingelheim Netherlands BV
2020 Phase 2 EUCTR2018-003081-14-NL Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2018-003081-14-DE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2019 Phase 2 EUCTR2018-003080-56-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2018-003081-14-HR Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003081-14-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003080-56-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
- Phase 2 EUCTR2018-003081-14-CZ Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
SCS Boehringer Ingelheim Comm. V
- Phase 2 EUCTR2018-003081-14-BE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
BI655130
Boehringer Ingelheim
2016 Phase 1 NCT02978690 France;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;Tunisia;
Brodalumab
Kyowa Hakko Kirin Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142430 -
2013 Phase 3 JPRN-JapicCTI-132057 -
Brodalumab 210mg SC
Kyowa Kirin Co., Ltd.
2016 Phase 4 NCT04183881 Japan;
CNTO1959
JANSSEN CILAG INTERNATIONAL NV
2019 Phase 3 EUCTR2018-003206-58-IT France;Germany;Italy;Spain;United Kingdom;
Janssen-Cilag International N.V.
2019 Phase 3 EUCTR2018-003206-58-GB France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-FR France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-ES France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-DE France;Germany;Italy;Spain;United Kingdom;
Calcitriol
Probiodrug AG
2007 - EUCTR2006-005344-83-DE Germany;
Efalizumab
Technische Universität Dresden
2007 - EUCTR2007-003922-70-DE Germany;
Guselkumab
Janssen Pharmaceutical K.K.
2015 Phase 3 NCT02343744 Japan;
Janssen-Cilag Ltd.
2019 Phase 3 NCT03998683 France;Germany;Italy;Spain;United Kingdom;
Infliximab
TOYAMA SATOSHI
2018 - JPRN-jRCTs031180367 Japan;
The University of Tokyo Hospital
2017 - JPRN-UMIN000027208 Japan;
Infliximab [infliximab biosimilar 3]
Pfizer
2019 - NCT03885089 Japan;
Ixekizumab
Eli Lilly and Company
2019 Phase 4 NCT03942042 Japan;
KHK4827
Kyowa Hakko Kirin Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142430 -
2013 Phase 3 JPRN-JapicCTI-132057 -
Kyowa Hakko Kirin Company, Limited
2013 Phase 3 NCT01782937 Japan;
KHK4827 140mg SC
Kyowa Kirin Co., Ltd.
2014 Phase 3 NCT02052609 Japan;
KHK4827 210mg SC
Kyowa Kirin Co., Ltd.
2014 Phase 3 NCT02052609 Japan;
LY3074828
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
MONOCLONAL ANTIBODY ANTI-IGG1
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2018-003081-14-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2018-003081-14-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2018-003081-14-GR Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España S.A.
2022 Phase 2 EUCTR2018-003080-56-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España, S.A.
2020 Phase 2 EUCTR2018-003081-14-ES Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim France
2020 Phase 2 EUCTR2018-003081-14-FR Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
2019 Phase 3 EUCTR2018-003080-56-FR Australia;China;France;Germany;Greece;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
2019 Phase 2 EUCTR2017-004231-37-FR France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
Boehringer Ingelheim Netherlands BV
2020 Phase 2 EUCTR2018-003081-14-NL Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2018-003081-14-DE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2019 Phase 2 EUCTR2018-003080-56-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2018-003081-14-HR Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003081-14-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003080-56-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
- Phase 2 EUCTR2018-003081-14-CZ Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
SCS Boehringer Ingelheim Comm. V
- Phase 2 EUCTR2018-003081-14-BE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Melatonin
Department of Dermatology, Children's Hospital of Chongqing Medical University
2021 Phase 0 ChiCTR2100044690 China;
Mirikizumab
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
Oxymatrine
General Hospital of Ningxia Medical University
2018 Phase 0 ChiCTR2100043193 China;
P32/98
Probiodrug AG
2007 - EUCTR2006-005344-83-DE Germany;
Placebo
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
Raptiva
Technische Universität Dresden
2007 - EUCTR2007-003922-70-DE Germany;
Risankizumab
AbbVie
2017 Phase 3 NCT03022045 Japan;
Secukinumab
Eli Lilly Japan K.K.
2018 Phase 3 JPRN-JapicCTI-184065 Japan, Asia except Japan, North America, South America, Europe, Oceania;
Novartis Pharma K.K.
2013 Phase 3 JPRN-JapicCTI-132305 -
Novartis Pharmaceuticals
2013 Phase 3 NCT02008890 Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
2013 Phase 3 NCT01952015 Japan;
Secukinumab 150 mg/1 mL Solution for injection
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-003086-34-BE Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Silikis 3µg/g Salbe
Probiodrug AG
2007 - EUCTR2006-005344-83-DE Germany;
Spesolimab
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2020 Phase 2 EUCTR2018-003081-14-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2018-003081-14-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim
2022 Phase 3 NCT05239039 -
2022 Phase 3 NCT05200247 Japan;
2020 Phase 2 NCT04399837 Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
2020 Phase 2 JPRN-JapicCTI-205387 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
2019 Phase 2 NCT03886246 Argentina;China;France;Germany;Japan;Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan;Thailand;Tunisia;Turkey;United States;
2019 Phase 2 NCT03782792 China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2018-003081-14-GR Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España S.A.
2022 Phase 2 EUCTR2018-003080-56-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim España, S.A.
2020 Phase 2 EUCTR2018-003081-14-ES Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim France
2020 Phase 2 EUCTR2018-003081-14-FR Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
Boehringer Ingelheim Netherlands BV
2020 Phase 2 EUCTR2018-003081-14-NL Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2018-003081-14-DE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2019 Phase 2 EUCTR2018-003080-56-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
Boehringer Ingelheim RCV GmbH & Co KG
2021 Phase 2 EUCTR2018-003081-14-HR Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003081-14-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
2021 Phase 2 EUCTR2018-003080-56-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
- Phase 2 EUCTR2018-003081-14-CZ Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
SCS Boehringer Ingelheim Comm. V
- Phase 2 EUCTR2018-003081-14-BE Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Yamada Nobuko
2021 Phase 2 JPRN-jRCT2041210087 Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea;Malaysia;Mexico;Netherlands;Philippines;Poland;Russia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;
TA-650
Mitsubishi Tanabe Pharma Corporation
2012 Phase 3 NCT01680159 Japan;
TG
Institute of dermatology, Chinese Academy of Medical Sciences
2011 - ChiCTR-TRC-12003542 China;
TREMFYA®
Janssen-Cilag International N.V.
2019 Phase 3 EUCTR2018-003206-58-GB France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-FR France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-ES France;Germany;Spain;United Kingdom;
2019 Phase 3 EUCTR2018-003206-58-DE France;Germany;Italy;Spain;United Kingdom;
Ustekinumab
Innovaderm Research Inc.
2010 Phase 3 NCT01091051 Canada;